Clinical Trial Update: Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study of acalabrutinib in combination with ACP-319 for Chronic Lymphocytic Leukemia. The trial is currently activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• ACP-319 (ACP-319)
• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING